The FDA has authorized marketing of the GSP Neonatal Creatine Kinase-MM kit. It’s the first test to aid in newborn screening for Duchenne Muscular Dystrophy (DMD), a rare genetic disorder that causes progressive muscle deterioration and weakness. While the number and type of diseases and conditions tested on each state’s newborn screening panel can vary, there has been a national effort to harmonize screening practices across state newborn screening programs in the U.S. (FDA
There will be no news brief next week on December 31, 2019.
Have a safe and happy holiday!